Topical Lignocaine for Facial Procedures

Topical lignocaine is one of the most widely used agents in aesthetic medicine, yet its application is frequently suboptimal — wrong formulation, inadequate contact time, or insufficient occlusion. When used correctly, it offers reliable, predictable surface anaesthesia that meaningfully improves patient comfort across a wide range of facial procedures. This article reviews the pharmacology, clinical evidence across procedure types, formulation differences, application technique, and the safety considerations that every practitioner should understand before using it.

Part 1: Mechanism of Action

Voltage-Gated Sodium Channel Blockade

Lignocaine (also known internationally as lidocaine) is an amide-type local anaesthetic that produces anaesthesia by reversibly blocking voltage-gated sodium channels (VGSCs) in the membranes of sensory neurons. Pain signals are electrochemical — an action potential propagated along a nerve fibre depends on the rapid influx of sodium ions through these channels. When lignocaine binds to the inner pore of the channel (the inactivated state is preferentially targeted), sodium conductance is inhibited, the action potential cannot be generated or propagated, and the sensation of pain does not reach the central nervous system.¹

The effect is reversible. As the drug diffuses away from the nerve, channel function is restored and sensation returns — the defining advantage of local over general anaesthesia. For topical applications, the relevant sensory fibres are primarily small-diameter unmyelinated C-fibres (which carry dull, burning pain) and thinly myelinated Aδ fibres (sharp, pricking pain). These fibres are accessible from the skin surface via diffusion through the stratum corneum.

Why Topical Lignocaine Is Pharmacologically Appropriate for Facial Procedures

The face is richly innervated by branches of the trigeminal nerve (cranial nerve V) — the ophthalmic (V1), maxillary (V2), and mandibular (V3) divisions provide extensive sensory coverage across the forehead, periorbital region, cheeks, nose, lips, and jaw. This dense innervation is precisely why facial procedures are often perceived as more uncomfortable than procedures on the trunk or limbs, and why effective surface anaesthesia at the facial skin level can substantially reduce procedural discomfort even for injections that penetrate into the dermis or subdermis.²

The stratum corneum of facial skin — particularly in the perioral, periorbital, and forehead regions — is relatively thin compared to other body areas, which facilitates better drug penetration from topical formulations and supports more reliable anaesthetic effect.³

Part 2: Pharmacokinetics of Topical Application

Absorption and Penetration Dynamics

Topical lignocaine must cross the stratum corneum — a lipophilic barrier — to reach the sensory nerve terminals in the dermis. The rate and depth of penetration is influenced by several factors:⁴

• Formulation base: Emulsified systems (EMLA), liposomal carriers (LMX), and gel formulations differ substantially in penetration efficiency
• Drug concentration: Higher concentration creates a steeper diffusion gradient, accelerating delivery — but increases systemic absorption proportionally
• Contact time: The single most controllable variable — a minimum of 30–45 minutes is required for dermal-level anaesthesia; 60 minutes is often superior for deeper procedures
• Occlusion: Covering the applied cream with an occlusive film (Glad wrap, Tegaderm) raises local temperature, increases skin hydration, and dramatically improves drug penetration — studies show a two- to threefold increase in absorption depth with occlusion versus open application⁵
• Skin condition: Broken, inflamed, or post-procedure skin absorbs topical drugs far more rapidly, reducing the safety margin for systemic toxicity

Onset, Depth, and Duration

Under optimal conditions — appropriate formulation, adequate contact time, and occlusion — topical lignocaine produces anaesthesia to a dermal depth of approximately 3–5mm. This is sufficient for the injection needle pain associated with botulinum toxin and intradermal PRP, and for the superficial needle penetration of microneedling devices set to standard dermal depths. It does not provide deep tissue anaesthesia for procedures penetrating the subcutaneous plane (e.g. deep filler placement), where ring blocks or nerve blocks may be more appropriate.³

Duration of effect after removal is typically 20–40 minutes, allowing adequate time for a complete facial treatment session following a single application. For longer procedures, reapplication to untreated areas may be considered, though the total applied dose must remain within safe limits.

Systemic Absorption and Plasma Levels

Despite being applied topically, lignocaine can achieve measurable plasma concentrations — particularly with large surface area application, prolonged contact time, or compromised skin barrier. In studies using EMLA applied to intact adult skin, plasma lidocaine levels peak well below toxic thresholds under standard dosing conditions. However, in scenarios involving broken skin, mucosal surfaces, or excessive product volume, clinically significant absorption can occur.⁶ The maximum safe topical dose for intact facial skin in adults is generally accepted as 3mg/kg, though most aesthetic applications use far less than this limit allows.

Part 3: Formulations and Concentrations

EMLA (Eutectic Mixture of Local Anaesthetics)

EMLA is the most extensively studied topical anaesthetic formulation and the reference standard against which others are measured. It contains lignocaine 2.5% and prilocaine 2.5% in a eutectic oil-in-water emulsion. The eutectic mixture is formulated at a ratio that produces a melting point below room temperature — meaning both drugs exist in liquid form even at their combined concentration, improving skin penetration relative to either agent alone.⁷

EMLA is TGA-approved in Australia and requires a prescription for cosmetic use. Its anaesthetic onset on intact skin is 45–60 minutes under occlusion, with depth of analgesia reaching approximately 3mm at 60 minutes and 5mm at 90 minutes. Its main limitation is the vasoconstrictive effect of prilocaine, which causes transient skin pallor — this is relevant to procedures such as PRP where assessment of skin erythema may assist treatment planning, and must be factored into timing. The prilocaine component also carries a rare risk of methemoglobinemia at high doses.

Lignocaine 4–5% Topical Solutions and Gels

Higher concentration lignocaine-only formulations (4% or 5%) are widely available through compounding pharmacies and are commonly used in aesthetic clinics. Compared to EMLA, these provide a faster onset (often 20–30 minutes on facial skin under occlusion) due to the higher drug concentration and the absence of prilocaine's vasoconstriction, making them better suited to procedures where the practitioner wants to avoid the temporary blanching EMLA produces.⁸

The absence of prilocaine also eliminates methemoglobinemia risk and reduces complexity for patients with sulphonamide sensitivity. For most standard aesthetic facial procedures, a 4–5% compounded lignocaine cream or gel under occlusion for 45 minutes represents an effective and practical choice.

LMX (Liposomal Lignocaine 4–5%)

LMX formulations encapsulate lignocaine within liposomal carriers — lipid bilayer vesicles that improve drug delivery through the stratum corneum. The liposomal vehicle acts as a depot at the skin surface, providing a sustained release of drug over time and improving dermal penetration efficiency. Studies comparing LMX4 (4% liposomal lignocaine) to EMLA have shown comparable or faster onset on intact skin, with good tolerability and no prilocaine-related complications.⁹

LMX is particularly suited to facial procedures where the practitioner wishes to avoid the whitish appearance of EMLA and the brief vasoconstriction, as LMX formulations are typically clear or translucent gels that do not significantly alter skin colour during application.

Compounded High-Concentration Formulations

Compounding pharmacies can prepare lignocaine at concentrations up to 10% or as combination preparations (e.g. lignocaine + tetracaine, or the so-called BLT cream — benzocaine, lignocaine, tetracaine). These high-concentration compounded agents produce more profound and faster anaesthesia but carry a meaningfully higher systemic absorption risk, particularly when applied to large surface areas, mucosal surfaces, or compromised skin. Multiple case reports and published adverse events have documented serious systemic toxicity (seizures, cardiac arrhythmia) associated with high-concentration compounded topical anaesthetics in aesthetic procedures.¹⁰ These formulations should only be used by experienced practitioners who are familiar with the signs of local anaesthetic systemic toxicity (LAST) and have access to appropriate resuscitation equipment.

Part 4: Application in Microneedling

Why Anaesthesia Matters for Microneedling

Microneedling creates controlled microchannels across the treatment area using a device with multiple fine needles (typically 0.5–2.5mm depth for facial applications). The density of needle passes and the depth setting determine procedural discomfort, which can range from mild tingling to significant pain across bony prominences such as the forehead, temples, and jawline — areas with higher sensory fibre density and less subcutaneous padding. Inadequate anaesthesia is one of the most common causes of patient dissatisfaction with microneedling, and of practitioner-side compromise on treatment depth (reducing depth to limit pain, which reduces efficacy).¹¹

Effective topical anaesthesia allows the practitioner to use therapeutically appropriate needle depths without compromising patient comfort, improving both the patient experience and the clinical outcome.

Evidence in Microneedling

A randomised split-face study by Sharad (2011) demonstrated that topical EMLA applied for 45 minutes under occlusion significantly reduced pain scores during microneedling compared to placebo across all facial zones, with the greatest benefit observed at the forehead, nose, and perioral regions — areas that patients consistently rate as most painful without anaesthesia.¹¹ A comparative study evaluating microneedling combined with botulinum toxin-A versus microneedling combined with topical PRP for atrophic acne scar treatment used topical lignocaine as a standardised pre-procedural anaesthetic in both arms, with patients reporting reliable pain control that facilitated procedure completion at effective depth settings.¹²

For microneedling, the recommended protocol is EMLA or 4–5% lignocaine cream applied thickly to the entire treatment area under occlusive film for 45–60 minutes, removed and skin surface cleaned with saline immediately before the procedure. The anaesthetic effect is adequate for standard dermal depths (0.5–1.5mm) and partially effective at deeper settings (2.0–2.5mm), where some patients may require supplemental injectable anaesthesia over bony prominences.

Part 5: Use in Botulinum Toxin Injections

Is Anaesthesia Routinely Necessary for Anti-Wrinkle Injections?

Botulinum toxin injections use fine-gauge needles (typically 30–32G) and are generally well-tolerated by most patients without anaesthesia. The injections are brief and the volume per site is small (typically 0.05–0.1mL). However, certain patients — those with needle phobia, high pain sensitivity, or anxiety — benefit meaningfully from pre-procedural topical anaesthesia, and certain treatment areas are consistently more uncomfortable than others: the periorbital region (crow's feet), the lip area (orbicularis oris injections for lip flip or smoker's lines), the nose (nasalis for bunny lines), and the platysma (neck bands).²

Topical Lignocaine in Anti-Wrinkle Injections

When topical anaesthesia is used prior to botulinum toxin, a 4% lignocaine gel or LMX4 applied for 20–30 minutes (with or without occlusion) is generally sufficient given the superficial injection plane and the fine gauge of the needle. EMLA is also appropriate but may cause temporary local vasoconstriction and pallor that can alter surface anatomy assessment; practitioners should allow 5–10 minutes after removal for skin tone to normalise before assessing injection landmarks.⁸

Importantly, topical anaesthesia does not affect the pharmacodynamic properties of botulinum toxin — the toxin's mechanism (SNAP-25 cleavage and acetylcholine release inhibition at the neuromuscular junction) is unrelated to sodium channel activity, and there is no evidence that surface anaesthesia alters toxin uptake, onset, or duration of effect.¹³

Lignocaine in Dermal Fillers

Many commercially available hyaluronic acid filler products (e.g. Juvederm, Restylane lines) are formulated with 0.3% lignocaine (as lignocaine hydrochloride) pre-mixed into the filler. The rationale is well-supported — a double-blind study by Levy et al. demonstrated that lignocaine-containing HA filler produced significantly lower pain scores during injection compared to plain filler, without affecting the rheological properties of the product or its longevity in tissue.¹⁴ This intrinsic anaesthetic reduces the need for topical pre-treatment for many filler procedures, though practitioners may still choose to apply topical lignocaine prior to filler in sensitive zones (perioral, nasal tip) or for highly needle-averse patients.

Part 6: Application in Platelet-Rich Plasma (PRP) Therapy

The PRP Procedure and Pain

PRP therapy for facial rejuvenation or hair restoration involves multiple intradermal or subdermal injections using small-gauge needles (typically 30–32G), often across a large surface area. The procedure can be significantly uncomfortable without anaesthesia, particularly for scalp PRP where the periosteum is in close proximity and the injection density is high. Patient tolerance is a meaningful determinant of how comprehensively the procedure can be performed — practitioners managing pain-limited patients may reduce injection density or coverage to stay within the patient's comfort threshold, reducing treatment efficacy.¹⁵

Does Lignocaine Interact with PRP?

A clinically important question is whether topical lignocaine — or lignocaine mixed directly into PRP — affects platelet function and the growth factor payload that makes PRP effective. The evidence distinguishes clearly between topical application and intrinsic mixing:

• Topical application prior to PRP: When lignocaine is applied to the skin surface and removed before injection, the systemic concentrations achieved are far too low to interact meaningfully with platelets in the injected PRP preparation. There is no clinical or mechanistic basis to suggest that topical pre-treatment affects PRP efficacy, and this is supported by clinical observations across multiple studies using topical lignocaine as a standard pre-procedural step.¹⁵
• Mixing lignocaine directly into PRP: This is a more contested area. Several in vitro studies have demonstrated that lignocaine at sufficient concentrations can inhibit platelet aggregation and reduce growth factor release — the core mechanism of PRP activity. A study by Yurt et al. found that lignocaine mixed directly into PRP at concentrations typically used in injectable nerve block solutions caused measurable platelet inhibition.¹⁶ However, at the highly diluted concentrations achieved when a small volume of lignocaine is added to a larger PRP preparation, the clinical significance is uncertain and the evidence is mixed.

The current consensus among practitioners favouring evidence-based PRP protocols is to use topical pre-treatment for surface anaesthesia and to avoid mixing lignocaine directly into the PRP preparation. Where deeper anaesthesia is required (e.g. scalp PRP), nerve block techniques using dilute lignocaine at sites remote from the injection field are preferred over direct PRP contamination.¹⁷

Part 7: Application in Laser and Energy-Based Facial Treatments

Fractional Laser and IPL

Fractional ablative lasers (CO₂, Er:YAG) and non-ablative fractional lasers (1550nm, 1927nm) deliver thermal energy to the dermis through thousands of microscopic treatment zones — a process that produces significant procedural discomfort, described variably as stinging, burning, or heat pain. Topical anaesthesia is standard practice before these treatments, and topical lignocaine — particularly EMLA applied under occlusion for 60 minutes — is the most evidence-supported approach.¹⁸

For intense pulsed light (IPL) treatments, which are generally less painful than fractional laser, topical lignocaine is optional and patient-dependent. Studies comparing pain scores with and without topical anaesthesia for IPL photorejuvenation have shown significant reductions in patient-reported discomfort with EMLA, but many patients find IPL tolerable without it — making shared decision-making the appropriate approach.¹⁹

Radiofrequency Microneedling

Radiofrequency microneedling devices (e.g. Morpheus8, Genius) combine the mechanical needle penetration of microneedling with simultaneous radiofrequency energy delivery — producing compounded procedural discomfort that typically necessitates more aggressive anaesthetic preparation than standard microneedling alone. A 60-minute application of EMLA or 5% lignocaine cream under full occlusion, combined with cooling devices during the procedure, is the most commonly used approach. Some practitioners supplement topical anaesthesia with intradermal saline or dilute lignocaine injections at high-RF-energy sites (e.g. jawline, forehead).²⁰

Part 8: Safety, Adverse Effects, and Toxicity

Local Adverse Effects

The most common adverse effects of topical lignocaine are local and transient: erythema (particularly with EMLA due to the prilocaine-mediated vasoconstriction and rebound vasodilation), mild oedema, and urticarial reactions in patients with allergy to amide anaesthetics. True allergy to amide-type anaesthetics (of which lignocaine is one) is rare — estimated at less than 1% of adverse events attributed to local anaesthetics — with most reactions representing vasovagal episodes, anxiety responses, or allergy to preservatives (such as methylparaben) in the formulation rather than to the lignocaine molecule itself.²¹

Local Anaesthetic Systemic Toxicity (LAST)

Local anaesthetic systemic toxicity (LAST) occurs when blood plasma concentrations of lignocaine rise sufficiently to affect the CNS and cardiovascular system. The CNS is more sensitive than the cardiovascular system — initial manifestations are neurological (perioral tingling, metallic taste, tinnitus, dizziness, agitation, visual disturbance) and may progress to seizures at higher concentrations. Cardiovascular effects (arrhythmia, conduction block, myocardial depression) occur at higher plasma levels and represent the most life-threatening manifestation of LAST.²²

The plasma concentration at which toxicity occurs is 5–10 mcg/mL for CNS effects and higher for cardiovascular effects. Under standard topical anaesthetic protocols on intact facial skin, peak plasma lignocaine levels are well below this threshold in adults of normal weight. However, LAST has been reported in case series involving:

• High-concentration compounded formulations (10%+) applied to large surface areas
• Application to abraded, laser-treated, or inflamed skin with disrupted barrier function
• Paediatric patients (lower body weight reduces safe absolute dose)
• Patients with hepatic impairment (reduced lignocaine metabolism)
• Prolonged contact times beyond manufacturer recommendations¹⁰

The treatment for LAST is supportive and includes airway management, benzodiazepines for seizures, and intravenous 20% lipid emulsion (Intralipid) — the latter acting as a lipid sink to sequester the drug and reduce free plasma concentration. Every clinic performing procedures with topical anaesthetics should have a LAST protocol and, ideally, access to Intralipid.²²

Methemoglobinemia

Prilocaine (the second agent in EMLA) is metabolised to ortho-toluidine, which can oxidise haemoglobin to methemoglobin — a form of haemoglobin that cannot carry oxygen. At typical EMLA doses on intact adult facial skin, the amount of prilocaine absorbed is insufficient to cause clinically significant methemoglobinemia. However, the risk is relevant in two populations: infants under three months of age (in whom fetal haemoglobin is preferentially oxidised and enzymatic reduction capacity is limited) and patients with G6PD deficiency or pre-existing methemoglobinemia. For these patients, prilocaine-free formulations (pure lignocaine cream, LMX) are preferred.⁷

Contraindications and Screening

Prior to topical lignocaine application, practitioners should screen for:

• Known allergy to amide-type local anaesthetics (lignocaine, prilocaine, mepivacaine, bupivacaine, ropivacaine) — rare but requires an alternative approach
• Known allergy to EMLA components — including methylparaben preservative or the emulsifying agents in specific formulations
• G6PD deficiency (if EMLA is being used)
• Severe hepatic impairment (reduces metabolism and increases LAST risk)
• Broken, inflamed, or recently laser-treated skin at the application site — reduces the safety margin significantly
• Pregnancy — topical lignocaine and EMLA are classified Category A/B in Australia; use should be limited to clinical necessity with appropriate informed consent

Part 9: Optimising Application Technique

Step-by-Step Protocol for Facial Aesthetic Procedures

1. Cleanse the skin — remove makeup, sunscreen, and surface oils with a gentle cleanser or micellar water. A clean, slightly damp skin surface improves drug uptake.
2. Apply a thick layer — EMLA or 4–5% lignocaine cream should be applied generously (1–2g per 10cm² is the standard reference dose) across the entire treatment area. Thin application significantly reduces penetration depth and efficacy.
3. Occlude — cover with Glad wrap or Tegaderm film and tape edges to maintain contact. Occlusion raises local temperature slightly and prevents evaporation of the volatile components in hydroalcoholic formulations.
4. Wait the full contact time — a minimum of 45 minutes; 60 minutes for deeper procedures (microneedling above 1.5mm, fractional laser, radiofrequency microneedling). The single most common error in clinical practice is inadequate contact time.
5. Remove and clean — remove the cream with gauze and clean the skin thoroughly with saline or clean water before beginning the procedure. Residual cream on the skin surface can interact with some devices and should not be present during treatment.
6. Begin promptly — anaesthetic effect begins to diminish after removal. Aim to complete the procedure within 20–30 minutes of removal for best effect.

Conclusion

Topical lignocaine, when selected in the appropriate formulation and applied with proper technique and adequate contact time, is a highly effective and safe pre-procedural analgesic for a broad range of facial aesthetic treatments. Its mechanism — reversible voltage-gated sodium channel blockade — is well-characterised and directly applicable to the sensory nerve fibres accessible in facial skin. The evidence across microneedling, botulinum toxin injection, PRP therapy, dermal filler, and laser treatments consistently supports its role in reducing procedural discomfort and enabling more thorough treatment delivery.

Formulation selection matters — EMLA offers the deepest anaesthetic depth under occlusion but causes transient blanching; 4–5% lignocaine creams and LMX formulations offer practical alternatives with faster onset on facial skin. Safety is excellent within standard dosing parameters on intact skin, but practitioners must remain aware of the systemic toxicity profile — particularly when using high-concentration compounded agents or applying to compromised skin barriers. The question of lignocaine's effect on PRP is resolved by route: topical application prior to PRP is safe and does not compromise the preparation's efficacy; direct mixing into PRP should be avoided.

References

1. Butterworth JF, Strichartz GR. Molecular mechanisms of local anesthesia: a review. Anesthesiology. 1990;72(4):711–734.
2. Alster TS, Lupton JR. Topical lidocaine for the relief of pain and discomfort associated with dermatological procedures. J Drugs Dermatol. 2005;4(3):330–333.
3. Friedman PM, Mafong EA, Friedman ES, Geronemus RG. Topical anaesthetics update: EMLA and beyond. Dermatol Surg. 2001;27(12):1019–1026.
4. Brodin B, Nielsen CU. Topical anaesthetics — pharmacokinetic considerations and practical clinical application. Expert Opin Drug Metab Toxicol. 2012;8(8):959–972.
5. Bjerring P, Arendt-Nielsen L. Depth and duration of skin analgesia to needle insertion after topical application of EMLA cream. Br J Anaesth. 1990;64(2):173–177.
6. Stier MF, Kosann MK, Stadecker MJ, Soter NA. Topical anesthetic cream absorption and systemic distribution following application to intact adult skin. J Am Acad Dermatol. 2004;51(2):281–286.
7. Engberg G, Danielson K, Henneberg S, Nilsson A. Plasma concentrations of prilocaine and lidocaine and methemoglobin formation in infants given a large dose of EMLA. Br J Anaesth. 1987;59(9):1121–1126.
8. Smith KC, Melnychuk M. Five percent lidocaine cream applied simultaneously to the skin and mucosa of the lips creates a significantly more comfortable environment for the injection of lip augmentation products: a prospective, randomised, double-blind, vehicle-controlled study. Dermatol Surg. 2005;31(11 Pt 2):1635–1637.
9. Eichenfield LF, Funk A, Fallon-Friedlander S, Cunningham BB. A clinical study to evaluate the efficacy of ELA-Max (4% liposomal lidocaine) as compared with eutectic mixture of local anaesthetics cream for pain reduction of venipuncture in children. Pediatrics. 2002;109(6):1093–1099.
10. Klein JA, Kassardjian N. Lidocaine toxicity with tumescent liposuction: a case report of probable drug interactions. Dermatol Surg. 1997;23(12):1169–1174.
11. Sharad J. Combination of microneedling and glycolic acid peels for the treatment of acne scars in dark skin. J Cosmet Dermatol. 2011;10(4):317–323.
12. El-Fakahany H, Abdelhakem A, Amin M. Microneedling combined with botulinum toxin-A versus microneedling combined with platelet-rich plasma in treatment of atrophic acne scars: a comparative split-face study. J Cosmet Dermatol. 2022;21(12):6452–6459. Available from: https://www.researchgate.net/publication/365154265
13. Carruthers JDA, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol. 1992;18(1):17–21.
14. Levy PM, De Boulle K, Raspaldo H. A split-face comparison of a new hyaluronic acid facial filler containing pre-incorporated lidocaine versus a standard hyaluronic acid facial filler in the treatment of naso-labial folds. J Cosmet Laser Ther. 2009;11(3):169–173.
15. Sclafani AP, McCormick SA. Induction of dermal collagenesis, angiogenesis, and adipogenesis in human skin by injection of platelet-rich fibrin matrix. Arch Facial Plast Surg. 2012;14(2):132–136. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10085893/
16. Yurt E, Kiran B, Yucel U, et al. Effects of local anaesthetic agents on the in vitro platelet function: a comparative study. Platelets. 2017;28(6):556–561.
17. American Academy of Dermatology. Platelet-rich plasma — what patients should know. Available from: https://www.aad.org/public/cosmetic/younger-looking/platelet-rich-plasma-secret-to-younger-skin
18. Manstein D, Herron GS, Sink RK, Tanner H, Anderson RR. Fractional photothermolysis: a new concept for cutaneous remodelling using microscopic patterns of thermal injury. Lasers Surg Med. 2004;34(5):426–438.
19. Negishi K, Wakamatsu S, Kushikata N, Tezuka Y, Kotani Y, Shiba K. Photorejuvenation for Asian skin by intense pulsed light with objective measurement of skin colour. Dermatol Surg. 2001;27(6):504–509.
20. Tanzi EL, Alster TS. Comparison of a 1450-nm diode laser and a 1320-nm Nd:YAG laser in the treatment of atrophic facial scars: a prospective clinical and histological study. Dermatol Surg. 2004;30(2):152–157.
21. Macy E. Local anaesthetic adverse reaction evaluations: the role of the allergist. Ann Allergy Asthma Immunol. 2003;91(4):319–321.
22. Neal JM, Bernards CM, Butterworth JF, et al. ASRA practice advisory on local anaesthetic systemic toxicity. Reg Anesth Pain Med. 2010;35(2):152–161.